Study shows drugs as effective as angioplasty for chest pain
BOSTON According to a new study, patients with chronic chest pain and considering angioplasty, but not in danger of a heart attack, should hold off.
The study, published in the New England Journal of Medicine, indicates that drugs are equally effective.
The early advantage for angioplasty at relieving pain in these non-emergency cases starts to fade within six months and vanishes after three years – much sooner than the five years doctors estimated last year after their first analysis of the study.
“This study should be enlightening and practice-changing for doctors and patients alike,” and should lead more to try drugs before resorting to the $40,000 heart procedure, said Duke University’s Dr. Eric Peterson, who co-wrote an editorial in the medical journal.
At least a third of angioplasties are done to relieve chest pain for people not in imminent danger. These patients are no more likely to die or have a heart attack if initially treated with drugs alone, the 2,287-patient study revealed.
Researchers did follow-up health surveys of about 70 percent of the study’s participants. At the start, 78 percent had chest pain.
Three months after treatment, 53 percent of patients who had angioplasties plus drug treatment and 42 percent of the patients who used drugs only were free of chest pain. Both groups continued to improve, and the gap started to narrow within six months. After three years, their scores on chest pain, quality-of-life and treatment satisfaction did not significantly differ.
One exception was among patients who started out with more severe chest pain and fared better with angioplasty. And not everyone did well on drugs alone — about one-third ultimately needed an angioplasty or heart bypass surgery.
The study patients also received an ideal mix of medicines, potentially including aspirin, cholesterol-lowering statins, nitrates, ACE inhibitors, beta-blockers and calcium channel blockers.
Sara Lee debuts ‘fragrance free’ Endust
DOWNERS GROVE, Ill. Sara Lee has added a new fragrance-free, hypoallergenic Endust spray to its line of aerosol cleaners. Endust Free debuted in August and will be in all retailers by the end of September.
The new product features a sleeker, curvier can, retails for $3.99 and is being promoted with the tagline ‘A quick clean that’s hypoallergenic.’ In addition to being free of odors, the product also contains fewer volatile organic compounds, a pollutant released by some aerosol products.
Wal-Mart increases profit outlook
BENTONVILLE, Ark. Despite ongoing concerns about the health of the U.S. and global economies, Wal-Mart today increased its full-year profit forecast after reporting record second-quarter results.
Total sales increased 10.4 percent to $101.6 billion and profits increased 9.3 percent to $3.385 billion, during the second quarter ended July 31. Same-store sales for the period increased 4.6 percent, excluding fuel sales, at Wal-Mart’s U.S. stores division and increased 3.7 percent, excluding fuel sales, at the Sam’s Club division.
“We have a great story to tell for this year’s second quarter,” said president and chief executive officer Lee Scott. “We continue to deliver on our mission of saving people money so they can live better. Each operating segment contributed to the quarter’s record sales.”
Wal-Mart’s great story also included mention of the health and wellness business as one of the six major merchandising units Scott said continues to gain market share in the United States.
“Our pharmacy prescription business has sustained high single-digit comparable-store sales growth,” said U.S. stores division president Eduardo Castro-Wright. “The $4 and $10 prescription program continue to drive pharmacy traffic. The $10, 90 day prescription offering resulted in a high double-digit fill rate increases.”
Other pharmacy details shared included what Castro-Wright called a, “substantial increase is pharmacy customers experience and faster checkout scores. The $4 or less price on more than 1,000 OTC products also generated strong customer response.”
Another area of emphasis on the call was about operational improvements that are driving improved financial results. Profits increased 14.6 percent to $0.86 per share from $0.75 the prior year, exceeding the company’s guidance that had been increased to a range of $0.82 to $0.84 on July 10. The company’s outlook for the third quarter calls for same store sales in a range of 1 percent to 2 percent and earnings per share of $0.73 to $0.76. Despite the modest outlook for third quarter comps, Wal-Mart boosted its full year earnings guidance to a range of $3.43 to $3.50 from guidance issued at the end of the last fiscal year of $3.30 to $3.43.
According to Scott, effective inventory management, especially in the United States and markets share gains in each of the company’s six major merchandising units contributed to an improved operational performance.
“Our company continues to manage cash flow in a way that will gives us the opportunity to participate in things that will benefit Wal-Mart long-term,” Scott said. “The combination of our strong operating performance coupled with strong capital efficiency allowed the company to report free cash flow through the first six months of almost $5 billion.”
Wal-Mart has been spending less money on opening new stores and also eased up on share repurchase activity during the second quarter. Wal-Mart added 73 stores worldwide and ended the second quarter with a total of 4,224 stores in the United States, including 2,572 supercenters, 915 discount stores, 594 Sam’s Clubs and 143 Neighborhood Markets. Internationally, Wal-Mart operates 3,192 stores in countries such as Mexico (1,074), Japan (392), the United Kingdom (346), Brazil (318), Canada (309), China (206), Costa Rica (154), Guatemala (147), El Salvador (74), Puerto Rico (55), Honduras (47), Nicaragua (46) and Argentina (24)